Notably, with a high cut-off of 80 μg Hb/g faeces, the proportion of FIT interval cancer was remarkably similar to that seen with gFOBT.35 In this study, we demonstrated that the proportion of interval cancers dropped from 54.1% in gFOBT-based screening to 16.3% in FIT-based screening at the cut-off of 15 μg Hb/g faeces, with incidence rates of interval cancers falling from 21 to 5 cases per 10,000 person-years. The gene discussed is GSTM1; the disease is cancer.